Target, across the briefings
CD19 across 3 cancers
CD19 is on the target list of 3 of the briefings. A drug aimed at it carries an FDA label naming the disease in 3, and is approved for some indication in 3.
| Disease | Label status | Furthest stage (Open Targets) | Distinct drugs | Cell-therapy trials |
|---|---|---|---|---|
| Diffuse large B-cell lymphoma | approved here Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, Loncastuximab Tesirine, Tafasitamab, Tisagenlecleucel | approved | 14 | 108 via CD19 |
| Follicular lymphoma | approved here Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, Tafasitamab, Tisagenlecleucel | approved | 14 | 57 via CD19 |
| Chronic lymphocytic leukemia | approved here Lisocabtagene Maraleucel | approved | 14 | 123 via CD19 |
"Approved here" means a drug Open Targets records as aimed at CD19 carries an FDA label that names that disease, per the briefing's openFDA stage. "Approved elsewhere" means the drug is approved for some other indication. Stage is the furthest Open Targets clinical stage among drugs aimed at the gene, in any indication; the database is reported as it is, and it lags some approvals. Cell-therapy trials are counted on the antigen the briefing maps the gene to, from ClinicalTrials.gov.